Want to see PCSA full AI Analyst Report?
Top Page
Processa Pharmaceuticals
(NASDAQ:PCSA)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.50
▼(-3.85% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily constrained by weak financial performance: zero revenue, recurring losses, negative cash flow, and a deteriorated balance sheet with negative equity, indicating high ongoing financing risk. Technical indicators are neutral with only mild near-term momentum, offering limited offset. Corporate events improve the outlook via substantial new funding and a refocused pipeline, but the associated recapitalization/dilution tempers the benefit, and valuation metrics remain unhelpful due to negative earnings.
Positive Factors
Funding runway
The substantial financing materially extends the company’s ability to fund research, clinical development and corporate operations, reducing near-term dependence on repeated capital raises while allowing management to pursue multiple Phase 2 programs.
Negative Factors
No product revenue
The company has no demonstrated commercial revenue base or operating scale, so its ability to create value depends on clinical success and eventual partnering or commercialization. Persistent losses increase execution risk and leave results highly dependent on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Funding runway
The substantial financing materially extends the company’s ability to fund research, clinical development and corporate operations, reducing near-term dependence on repeated capital raises while allowing management to pursue multiple Phase 2 programs.
Read all positive factors
Processa Pharmaceuticals (PCSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.81M
Dividend YieldN/A
Average Volume (3M)62.24K
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue GrowthN/A
EPS Growth90.37%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,793,386
10 Day Avg. Volume76,701
30 Day Avg. Volume62,241
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Processa Pharmaceuticals Business Overview & Revenue Model
Company Description
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The co...
How the Company Makes Money
Processa Pharmaceuticals does not have a recurring product-revenue business model because it is a clinical-stage biopharmaceutical company and, to the extent publicly available information indicates, it does not sell approved drugs. As a result, i...
Processa Pharmaceuticals Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -301.00 | 0.00 | 0.00 | 0.00 | -874.01K | 0.00 |
| EBITDA | -13.43M | -13.56M | -11.85M | -11.12M | -26.64M | -10.78M |
| Net Income | -13.44M | -13.56M | -11.85M | -11.12M | -27.42M | -11.43M |
Balance Sheet | ||||||
| Total Assets | 2.07M | 7.81M | 3.23M | 5.79M | 8.62M | 26.46M |
| Cash, Cash Equivalents and Short-Term Investments | 196.32K | 5.54M | 1.19M | 4.71M | 6.50M | 16.50M |
| Total Debt | 0.00 | 0.00 | 73.51K | 150.55K | 229.45K | 78.46K |
| Total Liabilities | 2.39M | 2.24M | 1.53M | 797.48K | 1.15M | 978.40K |
| Stockholders Equity | -317.34K | 5.58M | 1.70M | 4.99M | 7.47M | 25.49M |
Cash Flow | ||||||
| Free Cash Flow | -11.47M | -11.39M | -11.25M | -8.07M | -9.61M | -8.72M |
| Operating Cash Flow | -11.97M | -11.39M | -11.25M | -8.06M | -9.61M | -8.72M |
| Investing Cash Flow | -1.16M | -850.00K | -3.24K | -2.78K | 0.00 | 0.00 |
| Financing Cash Flow | 6.40M | 16.58M | 7.73M | 6.27M | -388.84K | 9.80M |
Processa Pharmaceuticals Technical Analysis
Negative
2.60
Price Trends
2.22
Negative
2.47
Negative
3.25
Negative
Market Momentum
-0.04
Positive
46.20
Neutral
16.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCSA, the sentiment is Negative. The current price of 2.6 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 2.22, and below the 200-day MA of 3.25, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 16.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PCSA.
Processa Pharmaceuticals Risk Analysis
Processa Pharmaceuticals disclosed 41 risk factors in its most recent earnings report. Processa Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Processa Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $22.15M | -1.44 | -150.61% | ― | ― | 38.55% | |
48 Neutral | $5.81M | -0.39 | -281.30% | ― | ― | 90.37% | |
45 Neutral | $7.67M | -0.75 | -201.06% | ― | ― | ― | |
45 Neutral | $17.23M | -1.10 | -66.69% | ― | -62.70% | -121.27% | |
44 Neutral | $3.67M | >-0.01 | -694.46% | ― | ― | -12.54% | |
42 Neutral | $8.73M | -0.32 | -246.04% | ― | ― | 66.94% |
* Healthcare Sector Average
PCSA
Processa Pharmaceuticals
2.17
-3.33
-60.55%
CANF
Can-Fite BioPharma
3.35
-9.65
-74.24%
SNGX
Soligenix
0.40
-2.73
-87.09%
LPCN
Lipocine
2.06
-0.96
-31.79%
COCP
Cocrystal Pharma
1.11
-0.43
-27.92%
PHGE
BiomX
0.13
-10.32
-98.72%
Processa Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Processa Pharmaceuticals Shareholders Approve Key Governance Changes
Positive
Aug 4, 2026
On July 30, 2026, Processa Pharmaceuticals held its 2026 Annual Meeting of Shareholders, where holders of at least one-third of the company’s voting power were present in person or by proxy, constituting a quorum. Shareholders elected all si...
Business Operations and StrategyExecutive/Board ChangesLegal ProceedingsM&A TransactionsPrivate Placements and Financing
Processa Pharmaceuticals acquires Vidya, raises strategic funding
Positive
Jul 29, 2026
On July 28, 2026, Processa completed the stock‑for‑stock acquisition of Vidya Therapeutics, bringing Vidya’s lead asset VT‑7208, a next‑generation CNS‑penetrant BTK inhibitor for immune‑mediated diseases, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.